Subscribe To

Price Alert Latest News Economic Calendar News

ASND / Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data

The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's stock has soared Monday nonetheless. The therapy, called TransCon OTH, is designed to treat adult patients with a disorder called hypoparathyroidism, in which the body produces abnormally low levels of parathyroid hormone. Read More

Demo Live Account See Partner Details

Content Topics

Ascendis

Pharma

After

Rejects

Hormone

Therapy

Application

Underlying

Clinical

Stock

ASND

Posted: May 1 2023, 13:57

Author Name: Proactive Investors

ASND News

By Zacks Investment Research
October 26, 2023

Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this tec

By Zacks Investment Research
September 15, 2023

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might h

By Seeking Alpha
September 5, 2023

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Rela

By Zacks Investment Research
August 10, 2023

How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%

The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has no

By Proactive Investors
May 1, 2023

Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data

The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's sto

By Seeking Alpha
April 27, 2023

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript.

By Seeking Alpha
April 16, 2023

Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity

We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for

By Zacks Investment Research
April 12, 2023

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisio

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.